183742-29-2

Basic information

• Product Name: 1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate
• Synonyms: 1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate;Ethyl 1-Boc-piperazine-3-carboxylate, 97%;1-(1,1-dimethylethyl)-3-ethyl 1,3-piperazinedicarboxylate;1-(tert-butyloxycarbonyl)-3-ethoxycarbonyl-piperazine;1-O-tert-butyl 3-O-ethyl piperazine-1,3-dicarboxylate;1-tert-butoxycarbonyl-3-ethoxycarbonylpiperazine;piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester
• CAS NO: 183742-29-2
• Molecular Formula: C₁₂H₂₂N₂O₄
• Molecular Weight: 258.31408
• EINECS: -0
• Mol File: 183742-29-2.mol

Chemical Properties

• Boiling Point: 384.421°C at 760 mmHg
• Flash Point: 186.292°C
• Appearance: /Solid
• Density: 1.128g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.484
• Storage Temp.: 2-8°C
• PKA: 6.57±0.40(Predicted)
• CAS DataBase Reference: 1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate(183742-29-2)
• EPA Substance Registry System: 1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate(183742-29-2)

Safety Data

• Hazardous Substances Data: 183742-29-2(Hazardous Substances Data)

Usage

Uses

1. Used in Research and Academia:
1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate is used as a research compound for its potential applications in various fields. Its unique structure and properties make it a valuable candidate for scientific investigations and the development of new chemical compounds.
2. Used as an Intermediate in Chemical Synthesis:
Due to its functional groups and reactivity, 1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate serves as an intermediate in the synthesis of other chemical compounds. Its presence in the synthesis process can contribute to the formation of desired products with specific properties and applications.
3. Used in Pharmaceutical Development:
Although not explicitly mentioned in the provided materials, the compound's potential applications in the medical field could include its use in pharmaceutical development. Piperazines, in general, have been used in the synthesis of various pharmaceuticals, and this specific compound may have similar potential.
4. Used in Chemical and Industrial Applications:
As a member of the piperazine class, 1-tert-Butyl 3-ethyl piperazine-1,3-dicarboxylate may find use in chemical and industrial applications, such as in the production of agrochemicals, dyes, or other specialty chemicals. Its unique structure and properties could contribute to the development of new products or processes in these industries.

InChI:InChI=1/C12H22N2O4/c1-5-12(9(15)16)8-14(7-6-13-12)10(17)18-11(2,3)4/h13H,5-8H2,1-4H3,(H,15,16)

Upstream product

• 1557288-75-1 tert-butyl (2-(1,3-dioxoisoindolin-2-yl)ethyl)((tributylstannyl)methyl)carbamate 
• 77361-32-1 N-(2-tert-butoxycarbonylaminoethyl)phthalimide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 129798-91-0 ethyl piperazine-2-carboxylate dihydrochloride 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 336818-63-4 ethyl 1-benzyloxycarbonyl-4-(tert-butoxycarbonyl)-2-piperazinecarboxylate 
• 89941-07-1 ethyl 2-piperazinecarboxylate 
• 218947-56-9 4-benzoyl-1-(4-hydroxy-benzenesulfonyl)-[1,4]diazepane-2-carboxylic acid methyl ester 

Downstream Products

• 942607-80-9 3-ethyl-1-tert-butyl-4-diphenylmethylpiperazine-1,3-dicarboxylate 
• 301673-16-5 tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate 
• 183742-28-1 ethyl 4-(1,1-dimethylethoxycarbonyl)-1-(phenylmethyl)-2-piperazinecarboxylate 
• 336817-63-1 ethyl 1-[N-(3,5-dichlorophenyl)carbamoyl]-4-tert-butoxycarbonyl-2-piperazinecarboxylate 
• 499780-58-4 4-[(tert-butoxy)carbonyl]-1-(4-fluorophenyl)piperazine-2-carboxylic acid 
• 864875-65-0 1-(4-but-2-ynyloxy-benzenesulfonyl)-4-(thiophene-2-carbonyl)-piperazine-2-carboxylic acid ethyl ester 
• 287403-52-5 4-(4-But-2-ynyloxy-benzenesulfonyl)-3-hydroxycarbamoyl-piperazine-1-carboxylic acid tert-butyl ester 
• 864875-68-3 1-(4-but-2-ynyloxy-benzenesulfonyl)-4-diethylcarbamoyl-piperazine-2-carboxylic acid ethyl ester 
• 864875-61-6 1-(4-but-2-ynyloxy-benzenesulfonyl)-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid ethyl ester 

Relevant articles and documents

An integrated console for capsule-based, automated organic synthesis

The current laboratory practices of organic synthesis are labor intensive, impose safety and environmental hazards, and hamper the implementation of artificial intelligence guided drug discovery. Using a combination of reagent design, hardware engineering, and a simple operating system we provide an instrument capable of executing complex organic reactions with prepacked capsules. The machine conducts coupling reactions and delivers the purified products with minimal user involvement. Two desirable reaction classes-the synthesis of saturated N-heterocycles and reductive amination-were implemented, along with multi-step sequences that provide drug-like organic molecules in a fully automated manner. We envision that this system will serve as a console for developers to provide synthetic methods as integrated, user-friendly packages for conducting organic synthesis in a safe and convenient fashion. This journal is

Catalytic Synthesis of N-Unprotected Piperazines, Morpholines, and Thiomorpholines from Aldehydes and SnAP Reagents

Commercially available SnAP (stannyl amine protocol) reagents allow the transformation of aldehydes and ketones into a variety of N-unprotected heterocycles. By identifying new ligands and reaction conditions, a robust catalytic variant that expands the substrate scope to previously inaccessible heteroaromatic substrates and new substitution patterns was realized. It also establishes the basis for a catalytic enantioselective process through the use of chiral ligands. SnAPcat! The identification of new ligands and reaction conditions provides a robust catalytic method for the synthesis of N-unprotected heterocycles using SnAP reagents. This catalytic variant expands the substrate scope to include previously inaccessible piperazines, morpholines, and thiomorpholines and establishes the basis for a catalytic enantioselective process through the use of chiral ligands.

SnAP reagents for the synthesis of piperazines and morpholines

Substituted piperazines and morpholines are valuable structural motifs in biologically active compounds, but are not easily prepared by contemporary cross-coupling approaches. In this report, we introduce SnAP reagents for the transformation of aldehydes into N-unprotected piperazines and morpholines. This approach offers simple, mild conditions compatible with aromatic, heteroaromatic, aliphatic, and glyoxylic aldehydes and provides mono- and disubstituted N-heterocycles in a single step.

HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (I) where Z is N or CHNR2 and X is NR2, O, S, S=O or SO2. Among other definitions for R, R1, W and Y, the compounds of formula (1) are further characterized by at least one of W or Y being CR3Ar2 where Ar is an aromatic or heteroaromatic ring (for example, where W or Y is a benzhydryl moiety).

INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION

The present invention relates to a compound of formula: (I), or a pharmaceutically acceptable salt thereof.

4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases

The present invention relates to bicyclic heterocycles of general formula wherein Ra to Rd, A to G and X are defined as in claim 1, the tautomers, the steroisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, their use for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.

ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS

Compound of the formula (B) are useful in treating disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof

The present invention relates to carboxylic acids and esters of general formula wherein Ar, R, R1, X1, X3, X4, Y and Y1 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof, as well as the use thereof for the production and purification of antibodies and as labelled compounds in RIA and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Sulfonyl derivatives

Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1is hydrogen, hydroxyl, nitro or the like; R2and R3are each independently hydrogen, halogeno or the like; R4and R5are each dependently hydrogen, halogeno or the like; Q1is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2is a single bond, oxygen or the like; Q3is, e.g., a group represented by formula (a): T1is carbonyl or the like; and X1and X2are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

Aminoquinazolines and their use as medicaments

Compounds of the formula having an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and air-ways, and the preparation thereof